Phase1/2a Clinical Trial of RPESC-derived RPE Transplantation as Therapy for Non-exudative Age-related Macular Degeneration

NIH资助的再生医学创新催化剂将： · 提供源干细胞系和正在开发的干细胞衍生产品的深入和独立表征， · 提供一个共享和分析临床试验（如适用）和细胞产品表征数据的平台，从而可能使干细胞衍生产品属性与临床结局相关，以及 · 为增强我们对临床结果的理解、改进生产方法和为未来RM产品开发提供信息奠定基础。 重要的是，RMIC将提高透明度，最终可能有助于临床级干细胞衍生产品的可重复性和标准化。

The NIH-funded Regenerative Medicine Innovation Catalyst will: • Provide in-depth and independent characterization of the source stem cell line and stem cell-derived products being developed, • Provide a platform for sharing and analysis of clinical trial (if applicable) and cell product characterization data, thereby potentially enabling correlation of stem cell-derived product attributes with clinical outcomes, and • Create a foundation for enhancing our understanding of clinical outcomes, refining production methods, and informing future RM product development. Importantly, the RMIC will promote transparency and ultimately may contribute to reproducibility and standardization of clinical grade stem cell-derived products.